DK0679400T3 - Orale doseringsformer af azithromycin til undgåelse af lægemiddelfødevareinteraktion - Google Patents

Orale doseringsformer af azithromycin til undgåelse af lægemiddelfødevareinteraktion

Info

Publication number
DK0679400T3
DK0679400T3 DK95302628T DK95302628T DK0679400T3 DK 0679400 T3 DK0679400 T3 DK 0679400T3 DK 95302628 T DK95302628 T DK 95302628T DK 95302628 T DK95302628 T DK 95302628T DK 0679400 T3 DK0679400 T3 DK 0679400T3
Authority
DK
Denmark
Prior art keywords
azithromycin
dosage forms
oral dosage
avoid drug
food interaction
Prior art date
Application number
DK95302628T
Other languages
Danish (da)
English (en)
Inventor
William J Curatolo
George H Foulds
Hylar L Friedman
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22883977&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0679400(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK0679400T3 publication Critical patent/DK0679400T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
DK95302628T 1994-04-29 1995-04-20 Orale doseringsformer af azithromycin til undgåelse af lægemiddelfødevareinteraktion DK0679400T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/235,069 US5605889A (en) 1994-04-29 1994-04-29 Method of administering azithromycin

Publications (1)

Publication Number Publication Date
DK0679400T3 true DK0679400T3 (da) 1999-12-06

Family

ID=22883977

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95302628T DK0679400T3 (da) 1994-04-29 1995-04-20 Orale doseringsformer af azithromycin til undgåelse af lægemiddelfødevareinteraktion

Country Status (31)

Country Link
US (2) US5605889A (fi)
EP (1) EP0679400B1 (fi)
JP (3) JPH07300420A (fi)
KR (1) KR100354310B1 (fi)
CN (1) CN1088362C (fi)
AP (1) AP566A (fi)
AT (1) ATE183395T1 (fi)
AU (1) AU709328B2 (fi)
CA (1) CA2148071C (fi)
CO (1) CO4560547A1 (fi)
DE (1) DE69511451T2 (fi)
DK (1) DK0679400T3 (fi)
DZ (1) DZ1877A1 (fi)
ES (1) ES2136247T3 (fi)
FI (1) FI952060A (fi)
GR (1) GR3031290T3 (fi)
HU (1) HUT75244A (fi)
IL (1) IL113437A (fi)
LV (1) LV10918B (fi)
MA (1) MA23533A1 (fi)
NO (1) NO314386B1 (fi)
NZ (1) NZ548384A (fi)
OA (1) OA10151A (fi)
RU (1) RU2128998C1 (fi)
SI (1) SI0679400T1 (fi)
TN (1) TNSN95046A1 (fi)
TW (1) TW499311B (fi)
UA (1) UA34464C2 (fi)
UY (1) UY23935A1 (fi)
YU (1) YU49483B (fi)
ZA (1) ZA953439B (fi)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1096862C (zh) † 1994-05-06 2002-12-25 辉瑞大药厂 阿齐霉素的控释剂型
ES2079327B1 (es) * 1994-12-13 1996-08-01 Lilly Sa Formulaciones farmaceuticas de cefaclor.
BR9607189A (pt) * 1995-02-08 1997-11-11 Yamanouchi Europ Bv Formas de dosagem oral contendo um antibiótico de b-lactama
US20060003447A1 (en) * 2003-12-30 2006-01-05 Richard Fike Dry powder cells and cell culture reagents and methods of production thereof
US6383810B2 (en) * 1997-02-14 2002-05-07 Invitrogen Corporation Dry powder cells and cell culture reagents and methods of production thereof
US20030212123A1 (en) * 1997-05-05 2003-11-13 Pfizer Inc. COX-2 selective carprofen for treating pain and inflammation in dogs
US6146655A (en) * 1997-08-29 2000-11-14 Softy-Flex Inc. Flexible intra-oral bandage and drug delivery system
US6129932A (en) * 1997-09-05 2000-10-10 Merck & Co., Inc. Compositions for inhibiting platelet aggregation
US6861411B1 (en) 1997-12-02 2005-03-01 Pfizer, Inc. Method of treating eye infections with azithromycin
US5955107A (en) * 1997-12-12 1999-09-21 Fmc Corporation Pharmaceutical suspension tablet compositions
DK0991415T3 (da) * 1997-12-22 2003-06-16 Schering Corp Faste, oralt indgivelige dosisformer for ribavirin og fremgangsmåde til fremstilling af disse
US5914128A (en) * 1997-12-22 1999-06-22 Schering Corporation Orally administrable solid dosage form
US5916594A (en) * 1997-12-22 1999-06-29 Schering Corporation Process of making solid ribavirin dosage forms
US6239112B1 (en) * 1998-07-09 2001-05-29 Merial, Inc. Water miscible macrolide solutions
FR2793690B1 (fr) * 1999-03-30 2003-01-03 Cll Pharma Formulations pharmaceutiques en macrolides seuls ou associes a d'autres principes actifs et leur utilisation en therapeutique
US6667060B1 (en) * 1999-03-31 2003-12-23 Janssen Pharmaceutica N.V. Pregelatinized starch in a controlled release formulation
US7056893B2 (en) * 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
US6239113B1 (en) * 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
IL141438A0 (en) * 2000-02-23 2002-03-10 Pfizer Prod Inc Method of increasing the bioavailability and tissue penetration of azithromycin
US20030219405A1 (en) * 2002-01-16 2003-11-27 Yoshihiro Sokawa Oral administration of interferon-tau
AU2000270425A1 (en) * 2000-07-25 2002-02-13 Instituto De Investigacion En Quimica Aplicada S.C Single-step process for preparing 7,16-deoxy-2-aza-10-o-cladinosil-12-o-desosaminil-4,5-dihydr oxi-6-ethyl-3,5,9,11,13,15-hexamethylbicycle (11.2.1)hexadeca-1(2)-en-8-ona and obtaining a new form of 9-desoxo-9a-methyl-9a-aza-9a-homoerythromycin
CA2419873A1 (en) 2000-08-23 2002-02-28 Wockhardt Limited Process for preparation of anhydrous azithromycin
WO2002036735A2 (en) * 2000-11-06 2002-05-10 Invitrogen Corporation Dry powder cells and cell culture reagents and methods of production thereof
DE60139892D1 (de) * 2000-11-15 2009-10-22 Masao Sugamata Makrolidantibiotika für endometriose oder uterusmyome
HRP20010301A2 (en) * 2001-04-27 2001-12-31 Pliva D D New therapeutic indication for azithromycin in the treatment of non-infective inflammatory diseases
JP2004530703A (ja) * 2001-05-22 2004-10-07 ファイザー・プロダクツ・インク 結晶形アジスロマイシン
SI1390377T1 (sl) 2001-05-22 2006-06-30 Pfizer Prod Inc Nova kristalna oblika azitromicina
CZ2004232A3 (cs) * 2001-08-21 2005-10-12 Pfizer Products Inc. Jednorázová dávka azithromycinu
AU2006218279B2 (en) * 2001-09-28 2009-12-10 Novartis Ag Pharmaceutical compositions comprising colloidal silicon dioxide
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
DE60232005D1 (de) * 2001-10-18 2009-05-28 Teva Pharma Stabilisierte azithromycin-zusammensetzungen
EP1541134A3 (en) * 2001-10-18 2007-06-06 Teva Pharmaceutical Industries Limited Stabilized azithromycin compositions
US20080149521A9 (en) * 2001-10-18 2008-06-26 Michael Pesachovich Methods of stabilizing azithromycin
EP1455758A1 (en) * 2001-12-21 2004-09-15 Pfizer Products Inc. Directly compressible formulations of azithromycin
PL371125A1 (en) * 2001-12-21 2005-06-13 Pfizer Products Inc. Methods for wet granulating azithromycin
NZ534234A (en) * 2002-02-01 2007-05-31 Pfizer Prod Inc Dry granulated formulations of non-dihydrate form of azithromycin
EP1490031A1 (en) * 2002-03-07 2004-12-29 Vectura Limited Fast melt multiparticulate formulations for oral delivery
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US20100226989A1 (en) * 2002-04-12 2010-09-09 Elan Pharma International, Limited Nanoparticulate megestrol formulations
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
US9101540B2 (en) 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
BG748Y1 (bg) * 2002-07-02 2005-06-30 "BALKANFARMA-RAZGRAD" AD A{ô­{òM{}ö{ }{GC}{D A{DAAAAAAAAAAAAAAAAAAAAAAAAAA ЛЕКАРСТВЕНАБФОРМАБББББББББББББББББББББББББББББББББФЕДЙГБФЕХгЦдв@ЖЦЩФ@@@@@@@@@@@
EP1594762A1 (en) * 2003-02-19 2005-11-16 Teva Pharmaceutical Industries Limited Methods of stabilizing azithromycin during storage by packaging in a gas impermeable container
BRPI0410098A (pt) * 2003-05-06 2006-05-16 Nirmal Mulye formulação de liberação controlada de derivados de eritromicina
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
ATE421882T1 (de) * 2003-07-24 2009-02-15 Pliva Hrvatska D O O Schnellösliches azithromycin in einzeldosisform
AR045142A1 (es) 2003-07-30 2005-10-19 Novartis Ag Composicion veterinaria masticable ductil de buen sabor
US20050089502A1 (en) * 2003-08-21 2005-04-28 Todd Schansberg Effervescent delivery system
AU2004294813A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Spray-congeal process using an extruder for preparing multiparticulate azithromycin compositions containing preferably a poloxamer and a glyceride
BRPI0417348A (pt) * 2003-12-04 2007-03-13 Pfizer Prod Inc processo de gelatinização por spray com utilização de uma extrusora para preparação de composições de droga cristalina multiparticulada contendo preferencialmente um poloxámero e um glicerìdeo
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
ATE399536T1 (de) * 2003-12-04 2008-07-15 Pfizer Prod Inc Verfahren zur herstellung von pharmazeutischen multiteilchenförmigen produkten
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
BRPI0416534A (pt) * 2003-12-04 2007-01-09 Pfizer Prod Inc composições multiparticuladas com estabilidade melhorada
AP2218A (en) * 2003-12-04 2011-04-20 Pfizer Prod Inc Azithromycin dosage forms with reduced side effects
RU2006119453A (ru) * 2003-12-04 2007-12-20 Пфайзер Продактс Инк. (Us) Получение посредством основанных на применении жидкостей способов лекарственные формы азитромицина с большим количеством частиц
US20050131079A1 (en) * 2003-12-10 2005-06-16 Pujara Chetan P. Cefdinir oral suspension
EP1699398A4 (en) * 2003-12-30 2007-10-17 3M Innovative Properties Co IMPROVING THE IMMUNE RESPONSE
US7468428B2 (en) * 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
JP4713104B2 (ja) * 2004-08-04 2011-06-29 ファイザー株式会社 アジスロマイシン類を有効成分とする苦味が抑制された安定な組成物
US20060046970A1 (en) * 2004-08-31 2006-03-02 Insite Vision Incorporated Topical otic compositions and methods of topical treatment of prevention of otic infections
US20060182806A1 (en) * 2004-11-08 2006-08-17 Mintong Guo Extended-release propranolol composition
AU2005325930B2 (en) * 2005-01-27 2012-01-19 Alembic Limited Extended release formulation of Levetiracetam
JP2008528583A (ja) * 2005-03-07 2008-07-31 テバ ファーマシューティカル インダストリーズ リミティド 経口懸濁用のアジスロマイシン粉末組成物
US20060198895A1 (en) * 2005-03-07 2006-09-07 Kotliar Eleonora M Azithromycin powder for oral suspension compositions
CA2606510C (en) 2005-05-26 2014-07-22 Dainippon Sumitomo Pharma Co., Ltd. Pharmaceutical preparation for oral administration comprising an imide compound
KR101465803B1 (ko) * 2005-08-10 2014-11-26 시오노기세이야쿠가부시키가이샤 구강내 붕괴 정제
US20070191271A1 (en) * 2006-02-10 2007-08-16 Dow Pharmaceutical Sciences Method for stabilizing polypeptides lacking methionine
US8187659B2 (en) 2006-05-02 2012-05-29 Jerry Robertson Real Estate Llc Solid medicament dosage form consumption aid
US20080014264A1 (en) * 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
US8124123B2 (en) * 2007-09-05 2012-02-28 Dow Pharmaceutical Sciences, Inc. Controlled release azithromycin solid dosages forms
WO2011122524A1 (ja) 2010-03-29 2011-10-06 アステラス製薬株式会社 放出制御医薬組成物
WO2013088274A1 (en) 2011-12-14 2013-06-20 Wockhardt Limited Anhydrous amorphous azithromycin composition free of azithromycin dihydrate
AU2013217633B2 (en) 2012-02-06 2017-01-12 Boehringer Ingelheim Animal Health USA Inc. Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
CN104168895B (zh) 2012-02-28 2020-02-21 首尔制药株式会社 包含西地那非作为活性成分的掩蔽苦味的高含量快速溶解膜
RU2498805C1 (ru) * 2012-07-23 2013-11-20 Открытое акционерное общество "Биосинтез" Твердая лекарственная форма азитромицина
CN104177457A (zh) * 2013-05-23 2014-12-03 长春海悦药业有限公司 一种阿奇霉素药物原料及其制剂和用途
CA2939604A1 (en) * 2013-11-11 2015-05-14 Forest Laboratories Holdings Limited Compositions and methods of treatment comprising fosfomycin disodium
RU2649834C1 (ru) * 2016-07-06 2018-04-04 Фармалидер С.А. Фармацевтическая композиция силденафила цитрата в форме суспензии для перорального применения

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI8110592A8 (en) * 1981-03-06 1996-06-30 Pliva Pharm & Chem Works Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof
US4382085A (en) * 1982-03-01 1983-05-03 Pfizer Inc. 4"-Epi erythromycin A and derivatives thereof as useful antibacterial agents
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
RU2066324C1 (ru) 1987-07-09 1996-09-10 Пфайзер Инк. Кристаллический дигидрат азитромицина и способ его получения
WO1989002271A1 (en) * 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents
SI9011409A (en) * 1990-07-18 1995-10-31 Pliva Pharm & Chem Works O-methyl azitromycin derivates, methods and intermediates for their preparation and methods for preparation of pharmaceuticals products which comprise them
WO1992006991A1 (fr) * 1990-10-15 1992-04-30 Taisho Pharmaceutical Co., Ltd. Erythromycine modifiee en 2' ou derive de cette substance
TW271400B (fi) 1992-07-30 1996-03-01 Pfizer
CA2173109A1 (en) 1993-10-01 1995-04-13 Kenneth Shyer Kornman Use of azithromycin for the treatment of adult periodontitis and topical compositions for this use
CN1096862C (zh) 1994-05-06 2002-12-25 辉瑞大药厂 阿齐霉素的控释剂型

Also Published As

Publication number Publication date
CO4560547A1 (es) 1998-02-10
TW499311B (en) 2002-08-21
CN1088362C (zh) 2002-07-31
NO951630L (no) 1995-10-30
IL113437A0 (en) 1995-07-31
NO951630D0 (no) 1995-04-28
DE69511451T2 (de) 1999-12-09
GR3031290T3 (en) 1999-12-31
CN1114879A (zh) 1996-01-17
AU709328B2 (en) 1999-08-26
YU27195A (sh) 1999-03-04
IL113437A (en) 2001-04-30
AP566A (en) 1996-11-22
AU1771195A (en) 1995-11-09
JPH07300420A (ja) 1995-11-14
FI952060A0 (fi) 1995-04-28
NZ548384A (en) 2008-04-30
DZ1877A1 (fr) 2002-02-17
JP2005015466A (ja) 2005-01-20
LV10918B (en) 1996-06-20
EP0679400B1 (en) 1999-08-18
KR100354310B1 (ko) 2002-12-26
USRE39149E1 (en) 2006-06-27
ATE183395T1 (de) 1999-09-15
TNSN95046A1 (fr) 1996-02-06
HUT75244A (en) 1997-05-28
US5605889A (en) 1997-02-25
HU9501206D0 (en) 1995-06-28
EP0679400A1 (en) 1995-11-02
FI952060A (fi) 1995-10-30
CA2148071C (en) 2000-10-17
DE69511451D1 (de) 1999-09-23
RU95106639A (ru) 1997-01-20
SI0679400T1 (en) 1999-10-31
ES2136247T3 (es) 1999-11-16
KR950028764A (ko) 1995-11-22
MA23533A1 (fr) 1995-12-31
RU2128998C1 (ru) 1999-04-20
UY23935A1 (es) 1995-09-12
NO314386B1 (no) 2003-03-17
ZA953439B (en) 1996-10-28
JP2008231120A (ja) 2008-10-02
YU49483B (sh) 2006-08-17
CA2148071A1 (en) 1995-10-30
AP9500728A0 (en) 1995-04-30
LV10918A (lv) 1995-12-20
OA10151A (en) 1996-12-18
UA34464C2 (uk) 2001-03-15

Similar Documents

Publication Publication Date Title
DK0679400T3 (da) Orale doseringsformer af azithromycin til undgåelse af lægemiddelfødevareinteraktion
IS4282A (is) Leysnistýrð skammtaform af Azithromycín
LU90115B1 (fr) Formulation orale de 2-méthyl-thiéno-benzodiazépine
IS4360A (is) Lyfjablanda í skammtaformi til munninntöku
CY2005007I1 (el) Φαρμακευτικες συνθεσεις που περιεχουν δαριφενακινη
DE69738089D1 (de) Feste orale Dosierungsformen enthaltend Valsartan
NO962490D0 (no) Orale formuleringer av S(+)-ibuprofen
DE69518331T2 (de) Orale zubereitungen
PT858325E (pt) Formulacao farmaceutica liofilizada estavel
DK0747050T3 (da) Farmaceutiske sammensætninger indeholdende irbesartan
DE59712959D1 (de) Orale pharmazeutische zubereitung enthaltend ibandronat
IS2184B (is) Lyfjaform með áfangalosun til inntöku um munn
NO962491D0 (no) Orale formuleringer av S(+)-etodolac
DE69822172D1 (de) Levosimendanhaltige oral anzuwendende arzneizusammensetzungen
DE69421621D1 (de) Verbesserte zahnfadenspenderphiole
NO20002439D0 (no) Nye orale doseringsformer for carvediol
DE69432149D1 (de) Orale Zubereitungen
DK0831820T3 (da) Oral farmaceutisk sammensætning af piperidinoalkanolforbindelser på opløsningsform
ITMI950961A0 (it) Composizioni farmaceutiche contenenti gemfibrozil
DE69413539T2 (de) Orale brausezusammensetzungen
DE69528372D1 (de) Orale behandlung
SE9402433D0 (sv) New oral pharmaceutical dosage form
SE9402432D0 (sv) New pharmaceutical dosage form
DE69814402D1 (de) Orale Arzneimittel zur Verbesserung von Aids-Symptomen
FI965187A (fi) 3-fenyyli-3-hydroksipiperidiinejä sisältäviä terapeuttisia koostumuksia